Oculus Innovative Sciences, Inc (NASDAQ:OCLS) Stock Lose By 6.78%


Dallas, Texas 03/26/2014 (FINANCIALSTRENDS) – Oculus Innovative Sciences, Inc (NASDAQ:OCLS) is a a global health care company that is involved in designing, manufacturing 7 marketing prescription & non-prescription products across 31 countries. It has announced the regulatory approval in Mexico for its new Microcyn60® Oral-Care family of products that is intended for use as the adjunct treatment in mouth & throat infections. Bruce Thornton, the executive VP of Oculus Innovative Sciences, Inc (NASDAQ:OCLS) said that this is a very exciting time for the company as it is the 1st Microcyn- based product that has been approved anywhere across the globe in antiseptic treatment of the mouth & throat infections.

This commercialization of Oculus Innovative Sciences, Inc (NASDAQ:OCLS)’s Microcyn Technology for the promising new-indication lays the foundation for introduction into various other international markets, particularly in Europe. As they did with the recent Mexican approval for Microcyn in acne, they will leverage the Mexican approval for oral-care by using its approved dossier in their submission to the European notified-body for CE-Mark approval. This 2-step approach to the regulatory submissions provides Oculus Innovative Sciences, Inc (NASDAQ:OCLS) the opportunity to migrate all these new products into Europe in the fastest time possible.

The 1st oral-care product that was launched by Oculus Innovative Sciences, Inc (NASDAQ:OCLS)’s Latin American partner, named More Pharma, will now be Microdacyn60 Bucofaringeo. More Pharma’s sales team intends to effectively target the general practitioners and ear, nose & throat specialists in the mid-2014, and will enlighten these health care professionals to all the advantages of the Microdacyn60 Bucofaringeo much advance of 2014 fall/winter cold & flu season. Oculus Innovative Sciences, Inc (NASDAQ:OCLS) who is More Pharma’s Chief Executive officer said that with the rising global concerns about overuse and the misuse of various antibiotics in treatment of the pathogen-related infections, the safe & effective oral-antiseptic like Microdacyn60 Bucofaringeo, will be very warmly received by the Mexican health care community.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.